Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 16Ovarian Neoplasms 9Breast Neoplasms 9Fallopian Tube Neoplasms 5Carcinoma, Ovarian Epithelial 5Squamous Cell Carcinoma of Head and Neck 4Neoplasm Metastasis 3Lung Neoplasms 3Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3Carcinoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Non Small Cell Lung Carcinoma NSCLC 2Neoplasms, Unknown Primary 2Neoplasms 2NSCLC 2Melanoma 2Esophageal Neoplasms 2Adenocarcinoma 2Urologic Neoplasms 1Urogenital Neoplasms 1Unresectable Stage III NSCLC 1Triple Negative Metastatic Breast Cancer 1Thyroid Neoplasms 1Thrombocytopenia 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236aldesleukin 134Cyclophosphamide 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 67dabrafenib 65fludarabine phosphate 61sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35cobimetinib 32Magnetic Resonance Spectroscopy 32Introns 30Specimen Handling 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Melanoma × CP protocol × Clear all
NCT06008106 2024-06-28

Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

Shanghai Kechow Pharma, Inc.

Phase 3 Recruiting
165 enrolled
Dermatologic

Melanoma

NCT00111007 2014-10-31

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

Bayer

Phase 3 Completed
270 enrolled 15 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡